Using AMH levels to predict infertility risk in children with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the levels of Antimüllerian Hormone (AMH) in children aged 3 to 14 who are newly diagnosed with cancer and treated with chemotherapy or pelvic irradiation. The study categorizes participants into high, moderate/low, and no risk groups based on their treatment regimens and aims to identify those at risk of reduced ovarian reserve. By monitoring AMH levels before and after treatment, the study seeks to provide insights into fertility preservation options for young patients who may face infertility due to cancer treatments. Follow-up assessments will occur annually for the first three years and then every two years until the study concludes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):

  * High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation
  * Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.
  * No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.

Exclusion Criteria:

* CNS (central nervous system) irradiation, cerebral tumour
* Current or previous ovarian disease/surgery
* Familial history of premature ovarian failure (no iatrogenic or surgical origins)
* Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction)
* Genetic/congenital disorders inducing mental retardation

Where it's running

• Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
  Montegnée, Liège, Belgium Recruiting
• Universitair Ziekenhuis Antwerpen
  Antwerp, Belgium Recruiting
• Hôpital Universitaire Reine Fabiola (HUDERF)
  Brussels, Belgium Recruiting
• Universitair Ziekenhuis Brussels
  Brussels, Belgium Recruiting
• Universitair Ziekenhuis Leuven
  Leuven, Belgium Recruiting
• Centre Hospitalier Régional (CHR)-Citadelle
  Liège, Belgium Recruiting

Study contacts

• Principal investigator: Alina Ferster — Queen Fabiola children's university hospital- Belgium
• Study coordinator: Isabelle Demeestere, PhD
• Email: isabelle.demeestere@ulb.be
• Phone: +32 2 555 65 92

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Follicular Flushing During Abdominal Egg Retrieval in Women with Low Egg Reserve

  This study tests whether rinsing the egg sacs during abdominal egg collection yields more eggs and more mature eggs for freezing in women with low ovarian reserve.

  Recruiting at 2 sites Centrum Clinic IVF Center · Ankara, Ankara and 1 other locations · NCT07877025

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.